☆ 4.7 Article

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

BRITISH JOURNAL OF CANCER (2011)

Related references

Note: Only part of the references are listed.

Editorial Material Oncology

Introduction

C. J. A. Punt et al.

ANNALS OF ONCOLOGY (2010)

Add to Collection

Article Oncology

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Glenwood D. Goss et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Eric Pujade-Lauraine et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Ursula A. Matulonis et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Editorial Material Oncology

Dual-agent molecular targeting of the ErbB2 receptor: Killing one bird with two stones

Hal W. Hirte et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG

Jacobus Pfisterer et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.